10 results
Part 11. Determine if accumulation of the fluorescent tracer bevacizumab-800CW can be detected for identification of soft tissue sarcoma during surgery.2. Identify two doses of bevacizumab-800CW that provide the best visualization of tumour tissue…
The objective of this study is to investigate the safety and efficacy of pertuzumab in combination with standard therapy, trastuzumab and a taxane.
Finding an effective and permanent treatment against keloid.
Pertuzumab is the investigational agent being studied for the treatment of HER2-positive gastric cancer. This study is to compare the overall survival (OS) in patients treated with pertuzumab in addition to trastuzumab (Herceptin®) plus cisplatin…
Primary objectivesThe primary objective of this trial is to evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inbibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line…
Part 1 1. Determine if accumulation of the fluorescent tracer bevacizumab-800CW can be detected for identification of pancreatic cancer tissue during surgery.2. Identify two doses of conjugate that provide the best visualization of tumor tissue…
To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).
Assess the feasibility of preoperative treatment with pertuzumab and trastuzumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of withdrawal rate from surgery
The main objectives are to evaluate the efficacy (as measured byprogression free survival at 6 months) of pertuzumab combined withtrastuzumab (PH) or PH plus metronomic chemotherapy (PHM) in anelderly metastatic breast cancer population, and to…
PRIMARY OBJECTIVEPart 1: Safety Run-in PhaseThe primary objective for Part 1 of this study is to determine the safety and tolerability of pertuzumab in combination with either topotecan or paclitaxel.Part 2The primary objective for Part 2 of this…